LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

19.94 1.22

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.75

Максимум

19.95

Ключови измерители
By Trading Economics
Приходи	25M -43M
Продажби	-3.6M 65M
EPS	-0.48
Марж на печалбата	-65.788
Служители	298
EBITDA	-16M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+100.15% upside

Дивиденти
By Dow Jones
Следващи печалби	3.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-149M 1.7B
Предишно отваряне	18.72
Предишно затваряне	19.94

Настроения в новините

By Acuity

75%

25%

310 / 345 Класиране в Healthcare

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.05.2026 г., 23:46 ч. UTC

Пазарно говорене

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24.05.2026 г., 23:42 ч. UTC

Пазарно говорене

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24.05.2026 г., 23:11 ч. UTC

Пазарно говорене

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24.05.2026 г., 22:26 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24.05.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24.05.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24.05.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24.05.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24.05.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24.05.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24.05.2026 г., 22:11 ч. UTC

Пазарно говорене

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24.05.2026 г., 22:04 ч. UTC

Пазарно говорене

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

23.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

22.05.2026 г., 21:10 ч. UTC

Печалби

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.05.2026 г., 19:47 ч. UTC

Печалби

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22.05.2026 г., 19:17 ч. UTC

Пазарно говорене

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22.05.2026 г., 19:10 ч. UTC

Пазарно говорене

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22.05.2026 г., 18:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

22.05.2026 г., 18:54 ч. UTC

Пазарно говорене

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22.05.2026 г., 18:38 ч. UTC

Пазарно говорене

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22.05.2026 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22.05.2026 г., 18:09 ч. UTC

Пазарно говорене

Centralized Crypto Lending Slows in 1Q -- Market Talk

22.05.2026 г., 17:58 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

100.15% нагоре

12-месечна прогноза

Среден 39.91 USD 100.15%

Висок 57 USD

Нисък 29 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

310 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.